Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kinnate Biopharma Inc.

Latest From Kinnate Biopharma Inc.

Finance Watch: Four Biotech VC Funds Raise $1.7bn Combined

Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline. 

Finance Watch StartUps and SMEs

Finance Watch: Have Biopharma IPOs Hit Their Limit?

Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.

Financing Business Strategies

Finance Watch: The Growing $100m-Plus VC Club

Private Company Edition: Venture capital mega-rounds continue to add up, including recent financings for Connect Biopharma ($115m) and Synthego ($100m). Also, Civilization Ventures closed a new $35m fund and Triumvira launched with $55m.

Financing Innovation

Kinnate Raises $98m To Take Kinase Inhibitors Into The Clinic

The company’s next-generation kinase inhibitors are designed to target unaddressed mutations and overcome treatment resistance. Lead programs focus on BRAF Class II and III mutations and FGFR2/3.

Financing Business Strategies
See All

Company Information

UsernamePublicRestriction

Register